A 26% relative hazard reduction in recurrent ischemic stroke was observed (HR 0.74), with primary efficacy assessed as time to first ischemic stroke. OCEANIC-STROKE trial data show asundexian cuts ...
News Medical on MSN
Novel neuroprotective drug improves recovery after acute ischemic stroke
Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting ...
Ashkan Shoamanesh, MD, discusses a secondary analysis of the efficacy and safety of the factor XIa inhibitor asundexian by ...
For patients with non-large vessel occlusion, acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase ...
For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor ...
The AHA/American Stroke Association released updated recommendations for early management of patients with acute ischemic stroke.
Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results